Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and effectiveness of SARS-CoV-2 vaccines for patients with intractable hepatobiliary diseases: A multicenter, questionnaire-based, cross-sectional study.
Tanifuji A, Ohfuji S, Matsumoto K, Abe M, Komori A, Takahashi A, Kawata K, Sato K, Joshita S, Umemura T, Ueno M, Nakayama N, Kakisaka K, Arinaga-Hino T, Ito K, Kanai S, Miura R, Arizumi T, Asaoka Y, Ito T, Shimizu T, Yoshida H, Ohta M, Mizuno S, Isayama H, Morimoto Y, Mochida S, Ohira H, Tanaka A. Tanifuji A, et al. Among authors: arizumi t. Hepatol Res. 2024 Feb 1. doi: 10.1111/hepr.14018. Online ahead of print. Hepatol Res. 2024. PMID: 38300669
A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer.
Nakai Y, Isayama H, Sasaki T, Sasahira N, Ito Y, Kogure H, Togawa O, Matsubara S, Arizumi T, Yagioka H, Yashima Y, Kawakubo K, Mizuno S, Yamamoto K, Hirano K, Tsujino T, Ijichi H, Toda N, Tada M, Kawabe T, Omata M. Nakai Y, et al. Among authors: arizumi t. Oncology. 2009;77(5):300-3. doi: 10.1159/000259616. Epub 2009 Nov 17. Oncology. 2009. PMID: 19923869
Bezafibrate for the treatment of primary sclerosing cholangitis.
Mizuno S, Hirano K, Tada M, Yamamoto K, Yashima Y, Yagioka H, Kawakubo K, Ito Y, Kogure H, Sasaki T, Arizumi T, Togawa O, Matsubara S, Nakai Y, Sasahira N, Tsujino T, Isayama H, Kawabe T, Omata M, Koike K. Mizuno S, et al. Among authors: arizumi t. J Gastroenterol. 2010 Jul;45(7):758-62. doi: 10.1007/s00535-010-0204-x. Epub 2010 Feb 3. J Gastroenterol. 2010. PMID: 20127368
Impact of S-1 on the survival of patients with advanced pancreatic cancer.
Nakai Y, Isayama H, Sasaki T, Sasahira N, Ito Y, Kogure H, Togawa O, Matsubara S, Arizumi T, Yagioka H, Yashima Y, Kawakubo K, Mizuno S, Yamamoto K, Hirano K, Tsujino T, Ijichi H, Tateishi K, Toda N, Tada M, Omata M, Koike K. Nakai Y, et al. Among authors: arizumi t. Pancreas. 2010 Oct;39(7):989-93. doi: 10.1097/MPA.0b013e3181d91936. Pancreas. 2010. PMID: 20467352
Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy.
Sasaki T, Isayama H, Nakai Y, Togawa O, Kogure H, Ito Y, Yamamoto K, Mizuno S, Yagioka H, Yashima Y, Kawakubo K, Arizumi T, Matsubara S, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K. Sasaki T, et al. Among authors: arizumi t. Cancer Chemother Pharmacol. 2011 Apr;67(4):847-53. doi: 10.1007/s00280-010-1360-7. Epub 2010 Jun 20. Cancer Chemother Pharmacol. 2011. PMID: 20563811
Impact of introduction of wire-guided cannulation in therapeutic biliary endoscopic retrograde cholangiopancreatography.
Nakai Y, Isayama H, Tsujino T, Sasahira N, Hirano K, Kogure H, Sasaki T, Kawakubo K, Yagioka H, Yashima Y, Mizuno S, Yamamto K, Arizumi T, Togawa O, Matsubara S, Yamamoto N, Tada M, Omata M, Koike K. Nakai Y, et al. Among authors: arizumi t. J Gastroenterol Hepatol. 2011 Oct;26(10):1552-8. doi: 10.1111/j.1440-1746.2011.06788.x. J Gastroenterol Hepatol. 2011. PMID: 21615792
Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer.
Isayama H, Nakai Y, Yamamoto K, Sasaki T, Mizuno S, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Arizumi T, Togawa O, Ito Y, Matsubara S, Yamamoto N, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M, Koike K. Isayama H, et al. Among authors: arizumi t. Oncology. 2011;80(1-2):97-101. doi: 10.1159/000328767. Epub 2011 Jun 13. Oncology. 2011. PMID: 21677453 Clinical Trial.
Duodenal invasion is a risk factor for the early dysfunction of biliary metal stents in unresectable pancreatic cancer.
Hamada T, Isayama H, Nakai Y, Togawa O, Kogure H, Kawakubo K, Tsujino T, Sasahira N, Hirano K, Yamamoto N, Arizumi T, Ito Y, Matsubara S, Sasaki T, Yagioka H, Yashima Y, Mohri D, Miyabayashi K, Mizuno S, Nagano R, Takahara N, Toda N, Tada M, Omata M, Koike K. Hamada T, et al. Among authors: arizumi t. Gastrointest Endosc. 2011 Sep;74(3):548-55. doi: 10.1016/j.gie.2011.04.046. Epub 2011 Jul 26. Gastrointest Endosc. 2011. PMID: 21794859
The results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial.
Tsujino T, Isayama H, Nakai Y, Ito Y, Togawa O, Toda N, Arizumi T, Kogure H, Yamamoto K, Mizuno S, Yashima Y, Yagioka H, Sasaki T, Matsubara S, Yamamoto N, Hirano K, Sasahira N, Tada M, Koike K. Tsujino T, et al. Among authors: arizumi t. J Gastroenterol. 2013 Aug;48(8):982-8. doi: 10.1007/s00535-012-0698-5. Epub 2012 Oct 24. J Gastroenterol. 2013. PMID: 23090004 Clinical Trial.
124 results